Clinic of Oncology and Department of Radiotherapy, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow Branch, Garncarska 11, 31-115, Cracow, Poland.
Department of Radiotherapy for Children and Adults, University Children's Hospital of Cracow, Wielicka 265, 30-663, Cracow, Poland.
Strahlenther Onkol. 2019 Sep;195(9):792-804. doi: 10.1007/s00066-019-01481-2. Epub 2019 Jun 18.
Presentation of long-term results of radiation treatment in patients with T1 glottic cancer and evaluation of prognostic factors.
We performed a retrospective analysis in a group of 569 patients with T1 squamous cell glottic carcinoma treated with radiotherapy at the Center of Oncology in Cracow between 1977 and 2007. In all, 503 (88%) patients presented with T1a stage disease and 66 (12%) with T1b. Anterior commissure infiltration was present in 179 (31%) patients. Average hemoglobin level prior to therapy was 13.9 g/dl. Using the body mass index (BMI), 114 (20%) patients were underweight, and 91 (16%) were overweight. Median time between collecting tumor specimen and beginning of radiotherapy was 56 days (range 14-145 days). Treatment regimen was normofractionated with single fraction ≤2 Gy in 102 (18%) and hypofractionated in 467 (82%) patients.
The 5‑ and 10-year overall survival (OS), disease-specific survival (DSS) and local control (LC) rates were 85 and 68%, 88 and 86%, 89 and 87%, respectively. Multivariate analysis showed that tobacco smoking, low hemoglobin level (<13 g/dl), anterior commissure infiltration, fraction dose ≤2 Gy and time from collecting specimen to beginning of therapy longer than 30 days had negative impact on LC and DSS. Patients' age over 60 years, worse performance status and malnutrition (BMI <18.5) had negative impacts on OS.
Radiotherapy is a highly effective treatment method in patients with T1N0M0 glottic cancer. LC and DSS may be improved following hypofractionation, smoking cessation, and shortening of waiting-time until start of treatment. OS was mainly influenced by nutritional and performance status.
介绍 T1 声门型喉癌患者放射治疗的长期结果,并评估预后因素。
我们对 1977 年至 2007 年在克拉科夫肿瘤中心接受放射治疗的 569 例 T1 鳞状细胞声门型喉癌患者进行了回顾性分析。所有患者中,503 例(88%)为 T1a 期疾病,66 例(12%)为 T1b 期。179 例(31%)患者前联合浸润。治疗前平均血红蛋白水平为 13.9g/dl。根据体重指数(BMI),114 例(20%)患者体重不足,91 例(16%)患者超重。从收集肿瘤标本到开始放疗的中位时间为 56 天(范围 14-145 天)。治疗方案为常规分割,单次分割≤2Gy 的有 102 例(18%),低分割的有 467 例(82%)。
5 年和 10 年总生存率(OS)、疾病特异性生存率(DSS)和局部控制率(LC)分别为 85%和 68%、88%和 86%、89%和 87%。多因素分析显示,吸烟、低血红蛋白水平(<13g/dl)、前联合浸润、分割剂量≤2Gy 以及从标本采集到开始治疗的时间超过 30 天与 LC 和 DSS 不良相关。患者年龄大于 60 岁、体力状态较差和营养不良(BMI<18.5)与 OS 不良相关。
放疗是 T1N0M0 声门型喉癌患者的一种非常有效的治疗方法。通过实施低分割、戒烟和缩短治疗开始前的等待时间,可改善 LC 和 DSS。OS 主要受营养和体力状态的影响。